LPAR2 and gastric cancer: The results from our ECIS and hemocytometer proliferation assays showed that the LPA-induced proliferation activity of the gastric cancer cells was significantly abrogated (p < 0.01) by the LPAR2 antagonist as well as by the treatment with Ki16425 (Figure 2A,B and Supplementary Figure S2B), and that the effect of the LPAR2 antagonist was similar to that of Ki16425.